Still, NSCLC patients harboring activating mutations in HER2 exhibit significantly better outcomes compared with those harboring sensitizing EGFR mutations, except for EGFR exon 20 insertions [67]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.